Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

University of New Mexico (UNM)

Status and phase

Completed

Phase 1

Conditions

Cervical Cancer

Treatments

Drug: Topotecan

Drug: Cisplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00320983

1601C

Details and patient eligibility

About

A Phase I Study of Adjuvant Topotecan and Cisplatin with Concurrent Radiation Therapy for Advanced Cervical Cancer.

Full description

Examines the effects of Topotecan and Cisplatin with radiation for advanced cervical cancer

Enrollment

11 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with histologically confirmed advanced cervical carcinoma who, following optional surgical staging, are not deemed to be curable by either surgery or radiotherapy alone. This includes patients with stages IIB, IIIA, IIIB or IVA and stages IB or IIA who in addition have one of the following risk factors:
- Primary tumor > 6 cm
- Positive pelvic and/or para-aortic lymph nodes (resected or unresected)
- Positive surgical margins
- Depth of invasion greater than 50 % and positive capillary-lymphatic space involvement
- Eligible cell types include squamous, adenosquamous and adenocarcinoma of the cervix
Patients may have measurable disease (defined as lesions which can be measured in at least two (2) dimensions by physical examination or any medical imaging technique). Inability to measure disease will not constitute exclusion criteria.
Patients with GOG performance status of 0, 1, or 2.
Patients will have recovered from the effects of recent surgery and should be free of clinically significant infection.
Patients must have adequate:
- Bone marrow function: WBC greater than or equal to 3,000 cells/mm3, platelet count greater than or equal to 100,000 cells/mm3, and granulocyte count greater than or equal to 1,500 cells/mm3.
- Renal function: Creatinine less than or equal to 2.0 mg/dl.
- Hepatic function: Bilirubin less than or equal to 1.5 x institutional normal, SGOT and alkaline phosphatase less than or equal to 3 x institutional normal.
Patients must have signed an approved informed consent.
Patients have met the pre-entry requirements specified in Section 7.0

Exclusion criteria

Patients with GOG performance of 3 or 4.
Patients with another malignancy, prior or concomitant, other than skin (excluding melanoma).
Patients with septicemia, severe infection, gastrointestinal bleeding, or intestinal obstruction.
Patients with anatomic abnormalities requiring modification of radiation fields (pelvic kidney, renal transplant, etc.).
Patient with recurrent cervical cancer
Patients who have received prior pelvic radiation
Pregnant women and women of childbearing potential not using an effective form of contraception.
History of thrombus (10/28/02)
History of unstable angina or MI within the past six months. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months. (10/28/02)